As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%. However over the last 3 years revenue has grown on average about 30.57% with more potential to increase further, especially with furthering of development of pipeline drugs. They currently have no debt as well on their balance sheet. Overall the only thing that scares me is along the lines of the new bill trump just passed about medications, and also the war in Israel which can effect their production. However if they are just able to normally produce their current two products I believe the stock could easily go back up to $3/share. If they are able to get their other drugs that are in the pipeline green lit then I can see this stock going a lot higher. As of rn willing to purchase up to $2.5 with a projection of the stock hitting around $3.20 by the end of the year
How well do narratives help inform your perspective?
Disclaimer
The user Zwfis holds no position in NYSEAM:PLX. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
